MedTrace Logo

Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals

NCT02616874 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-05-07

No results posted yet for this study

Summary

The BCN02-Romi study aims to evaluate a combined "kick and kill" strategy using the most immunogenic candidate vaccine available so far (HIVconsv) with the strongest latency reversal agent available at present time (romidepsin) in a cohort of early-treated HIV positive individuals.

Conditions

Interventions

DRUG

MVA.HIVconsv vaccine

Dose: 2x10e8 pfu, Interval: weeks 0 and 9.

DRUG

Romidepsin

Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5

Sponsors & Collaborators

  • Germans Trias i Pujol Hospital

    collaborator OTHER

  • Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

    collaborator OTHER

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Hospital de Sant Pau

    collaborator OTHER

  • HIVACAT

    collaborator UNKNOWN

  • University of Oxford

    collaborator OTHER

  • BCN Checkpoint

    collaborator INDUSTRY

  • IrsiCaixa

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-09-30
Completion
2017-10-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02616874 on ClinicalTrials.gov